Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.50 USD
-0.12 (-4.57%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.49 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Cellectis SA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 26 | 67 | 82 | 23 |
Cost Of Goods | NA | 2 | 31 | 36 | 11 |
Gross Profit | NA | 24 | 36 | 46 | 12 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 114 | 166 | 132 | 135 |
Income After Depreciation & Amortization | 0 | -90 | -131 | -85 | -124 |
Non-Operating Income | NA | 9 | 13 | 5 | 12 |
Interest Expense | NA | 18 | 8 | 18 | 4 |
Pretax Income | NA | -99 | -125 | -97 | -115 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | -8 | -11 | -16 | -13 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -99 | -125 | -97 | -115 |
Extras & Discontinued Operations | NA | -15 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -106 | -114 | -81 | -102 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -71 | -114 | -76 | -117 |
Depreciation & Amortization (Cash Flow) | NA | 18 | 17 | 10 | 7 |
Income After Depreciation & Amortization | 0 | -90 | -131 | -85 | -124 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 45.55 | 44.78 | 42.50 | 42.36 |
Diluted EPS Before Non-Recurring Items | NA | -2.17 | -2.55 | -1.91 | -2.41 |
Diluted Net EPS (GAAP) | NA | -2.33 | -2.55 | -1.91 | -2.41 |
Fiscal Year end for Cellectis SA falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 1.64 | 2.00 | 3.56 |
Cost Of Goods | NA | NA | 0.18 | 0.06 | 0.33 |
Gross Profit | NA | NA | 1.46 | 1.95 | 3.23 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 22.13 | 25.60 | 26.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -20.67 | -23.65 | -23.43 |
Non-Operating Income | NA | NA | 4.92 | 32.27 | 0.78 |
Interest Expense | NA | NA | 1.62 | 16.28 | 5.18 |
Pretax Income | NA | NA | -17.38 | -7.68 | -27.83 |
Income Taxes | NA | NA | 0.11 | 0.26 | 0.00 |
Minority Interest | NA | NA | 0.00 | -2.94 | -2.45 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -17.48 | -7.94 | -27.83 |
Extras & Discontinued Operations | NA | NA | 0.00 | -5.65 | -4.69 |
Net Income (GAAP) | NA | NA | -17.48 | -10.65 | -30.08 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 56.39 | 55.58 | 51.85 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.31 | -0.14 | -0.58 |
Diluted Net EPS (GAAP) | NA | NA | -0.31 | -0.19 | -0.58 |